Dishman Carbogen Amcis Limited provides contract research and manufacturing services to the pharmaceutical industry worldwide.
Flawless balance sheet and fair value.
Share Price & News
How has Dishman Carbogen Amcis's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DCAL's share price has been volatile over the past 3 months.
7 Day Return
IN Life Sciences
1 Year Return
IN Life Sciences
Return vs Industry: DCAL underperformed the Indian Life Sciences industry which returned 31.4% over the past year.
Return vs Market: DCAL underperformed the Indian Market which returned -5.4% over the past year.
Price Volatility Vs. Market
How volatile is Dishman Carbogen Amcis's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall StMarket Cool On Dishman Carbogen Amcis Limited's (NSE:DCAL) Earnings
4 weeks ago | Simply Wall StWhat Is Dishman Carbogen Amcis's (NSE:DCAL) P/E Ratio After Its Share Price Rocketed?
1 month ago | Simply Wall StDishman Carbogen Amcis Limited (NSE:DCAL) Analysts Just Cut Their EPS Forecasts Substantially
Is Dishman Carbogen Amcis undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: DCAL (₹152.65) is trading above our estimate of fair value (₹66.93)
Significantly Below Fair Value: DCAL is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: DCAL is good value based on its PE Ratio (13.6x) compared to the IN Life Sciences industry average (35.1x).
PE vs Market: DCAL is poor value based on its PE Ratio (13.6x) compared to the Indian market (12.6x).
Price to Earnings Growth Ratio
PEG Ratio: DCAL is good value based on its PEG Ratio (0.9x)
Price to Book Ratio
PB vs Industry: DCAL is good value based on its PB Ratio (0.4x) compared to the IN Life Sciences industry average (1.1x).
How is Dishman Carbogen Amcis forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DCAL's forecast earnings growth (14.9% per year) is above the savings rate (7.2%).
Earnings vs Market: DCAL's earnings (14.9% per year) are forecast to grow slower than the Indian market (18.9% per year).
High Growth Earnings: DCAL's earnings are forecast to grow, but not significantly.
Revenue vs Market: DCAL's revenue (7.7% per year) is forecast to grow faster than the Indian market (7.3% per year).
High Growth Revenue: DCAL's revenue (7.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DCAL's Return on Equity is forecast to be low in 3 years time (3.5%).
How has Dishman Carbogen Amcis performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DCAL has high quality earnings.
Growing Profit Margin: DCAL's current net profit margins (8.8%) are lower than last year (10.2%).
Past Earnings Growth Analysis
Earnings Trend: DCAL has become profitable over the past 5 years, growing earnings by 28.6% per year.
Accelerating Growth: DCAL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: DCAL had negative earnings growth (-14.3%) over the past year, making it difficult to compare to the Life Sciences industry average (-6.2%).
Return on Equity
High ROE: DCAL's Return on Equity (3.1%) is considered low.
How is Dishman Carbogen Amcis's financial position?
Financial Position Analysis
Short Term Liabilities: DCAL's short term assets (₹18.0B) exceed its short term liabilities (₹15.7B).
Long Term Liabilities: DCAL's short term assets (₹18.0B) exceed its long term liabilities (₹9.2B).
Debt to Equity History and Analysis
Debt Level: DCAL's debt to equity ratio (16.2%) is considered satisfactory.
Reducing Debt: DCAL had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: DCAL's debt is well covered by operating cash flow (63%).
Interest Coverage: DCAL's interest payments on its debt are well covered by EBIT (3.9x coverage).
What is Dishman Carbogen Amcis's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: DCAL's dividend (0.13%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.69%).
High Dividend: DCAL's dividend (0.13%) is low compared to the top 25% of dividend payers in the Indian market (2.73%).
Stability and Growth of Payments
Stable Dividend: DCAL is not paying a notable dividend for the Indian market, therefore no need to check if payments are stable.
Growing Dividend: DCAL is not paying a notable dividend for the Indian market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: DCAL is not paying a notable dividend for the Indian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DCAL's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Arpit Vyas (34yo)
Mr. Arpit Janmejay Vyas has been Group Managing Director of Dishman Carbogen Amcis Limited since November 28, 2018 and as its Director since April 7, 2012. He is the Global CFO at Carbogen Amcis AG. He ser ...
CEO Compensation Analysis
Compensation vs Market: Arpit's total compensation ($USD159.74K) is below average for companies of similar size in the Indian market ($USD358.82K).
Compensation vs Earnings: Arpit's compensation has been consistent with company performance over the past year.
|Chairman of the Board||no data||₹15.82m||0.0019% ₹441.5k|
|Group MD & Director||no data||₹12.00m||0.00064% ₹148.0k|
|Director of Global Marketing & Strategy and Director||3.33yrs||no data||no data|
|Whole Time Director||3.33yrs||₹12.00m||0.00064% ₹148.0k|
|Independent Director||3.33yrs||₹1.48m||no data|
|Independent Director||3.33yrs||₹1.90m||0.016% ₹3.6m|
|Independent Director||3.33yrs||₹1.33m||no data|
|Independent Director||3.33yrs||₹920.00k||no data|
|Independent Director||1.25yrs||no data||no data|
Experienced Board: DCAL's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Dishman Carbogen Amcis Limited's company bio, employee growth, exchange listings and data sources
- Name: Dishman Carbogen Amcis Limited
- Ticker: DCAL
- Exchange: NSEI
- Founded: 2007
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹23.118b
- Shares outstanding: 156.78m
- Website: https://www.dishmangroup.com
- Dishman Carbogen Amcis Limited
- Dishman Corporate House
- Opposite Jayantilal Park BRTS Bus Stop
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|540701||BSE (Mumbai Stock Exchange)||Yes||Equity Shares||IN||INR||Sep 2017|
|DCAL||NSEI (National Stock Exchange of India)||Yes||Equity Shares||IN||INR||Sep 2017|
Dishman Carbogen Amcis Limited provides contract research and manufacturing services to the pharmaceutical industry worldwide. It also manufactures and supplies marketable molecules, such as bulk drugs, intermediates, quaternary ammonium compounds, specialty chemicals, vitamins and chemicals, and disinfectants. The company was incorporated in 2007 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/10 13:00|
|End of Day Share Price||2020/07/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.